CN109674746A - A kind of Edaravone infusion set - Google Patents
A kind of Edaravone infusion set Download PDFInfo
- Publication number
- CN109674746A CN109674746A CN201910072044.8A CN201910072044A CN109674746A CN 109674746 A CN109674746 A CN 109674746A CN 201910072044 A CN201910072044 A CN 201910072044A CN 109674746 A CN109674746 A CN 109674746A
- Authority
- CN
- China
- Prior art keywords
- edaravone
- injection
- solution
- infusion set
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The embodiment provides a kind of Edaravone infusion sets, are related to field of pharmaceutical preparations, invent for convenience of using Edaravone Injection.Edaravone infusion set, which is characterized in that the soft bag including Edaravone Injection and for accommodating the Edaravone Injection；The Edaravone Injection includes: Edaravone, osmotic pressure regulator, antioxidant, cosolvent and water for injection；The Edaravone Injection volume is about or equal to 100mL.The present invention can be used for cerebral protective agent.
Description
Technical field
The present invention relates to field of pharmaceutical preparations more particularly to a kind of Edaravone infusion sets.
Background technique
Edaravone is a kind of cerebral protective agent (free radical scavenger).Clinical research prompts N- acetyl L-aminobutanedioic acid (NAA)
It is the mark of the viable neuronal cell of specificity, cerebral infarction early stage content is sharply reduced.
The common formulations of Edaravone are the injection of 30mg at present, quiet after appropriate normal saline dilution is added before use
Arteries and veins instils.The Edaravone of this kind of dosage form is needed in provisional configuration solution before use, and it not is very just that the injection of drug, which is used,
Benefit.
Summary of the invention
The main purpose of the embodiment of the present invention is, provides a kind of Edaravone Injection that can be easy to use.
In order to solve technical problem above, the embodiment of the invention provides a kind of Edaravone infusion sets, including according to
Da Lafeng injection and soft bag for accommodating the Edaravone Injection；The Edaravone Injection includes: according to reaching
La Feng, osmotic pressure regulator, antioxidant, cosolvent and water for injection；The Edaravone Injection volume is about or equal to
100mL。
Optionally, the osmotic pressure regulator is sodium chloride.
Optionally, the antioxidant includes sodium pyrosulfite and vitamin C.
Optionally, the cosolvent includes L-cysteine hydrochloride.
Optionally, the Edaravone Injection includes: the chlorination of the Edaravone of 30 parts by weight, 800-1000 parts by weight
The L-cysteine hydrochloride of sodium, the sodium pyrosulfite of 15-25 parts by weight, the vitamin C of 5-15 parts by weight and 5-15 parts by weight.
Optionally, the Edaravone Injection includes: 30mg Edaravone, 900mg sodium chloride, 20mg pyrosulfurous acid
Sodium, 10mg vitamin C, 10mg L-cysteine hydrochloride, the injection for making the Edaravone Injection volume 100ml
Water.
Optionally, the soft bag includes film, and the film includes outer layer, middle layer and internal layer；The middle layer includes poly- third
Alkene, polyenoid quasi polymer with unsaturated double-bond and transition metal salt.
Optionally, the middle layer includes that the polypropylene that occupies entire intermediate layer weight 85-99%, 1-15% have not
It is saturated the polyenoid quasi polymer of double bond, the transition metal salt of 1-15ppm.
Optionally, polyenoid quasi polymer with unsaturated double-bond is polyisoprene；The transition metal salt is tristearin
Sour cobalt.
The embodiment of the invention also provides a kind of preparation methods of above-mentioned Edaravone infusion set, comprising:
Osmotic pressure regulator is dissolved in water for injection and forms the first solution；
Antioxidant, cosolvent are dissolved in water for injection and form the second solution, and second solution is poured into described
In one solution, third solution is formed；
Edaravone is added in the third solution, is dissolved by heating at 50 DEG C or less, adjusts pH to 3.0- after cooling
4.5；
Water for injection is added in the third solution and supplies recipe quantity；
The third solution is subjected to micro-pore-film filtration and is poured into the soft bag, is sterilized.
Edaravone injecting assembly provided in an embodiment of the present invention and preparation method thereof directly mentions Edaravone Injection
For in soft bag, providing volume in the big infusion injection of 100mL or more, it can be injected directly into patient's body in clinical application
It is interior, without the process of provisional configuration solution, so that the injection of drug is more convenient, doctors and patients' time is saved, is improved efficiency.
Specific embodiment
The technical scheme in the embodiments of the invention will be clearly and completely described below, it is clear that described implementation
Example is only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, this field is common
Technical staff's every other embodiment obtained without making creative work belongs to the model that the present invention protects
It encloses.
Clinical study results show that Edaravone has apparent cerebral protection, can be obviously improved mind caused by cerebral ischemia
Through systemic symptom.In animal experiment, ischaemic recycling in 30 minutes intravenous injection gives Edaravone, can upon administration 60
The deterioration of cortex oedema is significantly inhibited when minute.
Edaravone is saved and is applied mostly in the form of injection.The dosage of clinical application at present is mostly 20ml, 30mg.This
It is it is easy to oxidize at inactive substance to encounter oxygen, and be also easy to produce because the molecular results of Edaravone Injection are unstable
Macromolecule impurity is done harm to huamn body.Therefore existing Edaravone Injection needs to be configured to large transfusion fluid before the injection more
In system.This mode causes Edaravone that may expose the risk for causing Edaravone to be oxidized in air again.
To solve the above-mentioned problems, one embodiment of the invention provides a kind of Edaravone infusion set, including Yi Dala
Give injection and the soft bag for accommodating the Edaravone Injection；The Edaravone Injection include: Edaravone,
Osmotic pressure regulator, antioxidant, cosolvent and water for injection；The Edaravone Injection volume is about or equal to 100mL.
Edaravone injecting assembly provided in an embodiment of the present invention, Edaravone Injection is provided directly in soft bag,
Volume is provided in the big infusion injection of 100mL or more, patient's body can be injected directly into clinical application, without facing
When configure the process of solution and save doctors and patients' time, improve efficiency so that the injection of drug is more convenient.
In another embodiment of the present invention, osmotic pressure regulator can be selected from one in sodium chloride, glucose, sorbierite
Kind is several, preferably can be sodium chloride.Cosolvent is selected from disodium hydrogen phosphate, sodium phosphate, potassium carbonate, L-cysteine salt
Hydrochlorate preferably can be L-cysteine hydrochloride, specifically be, for example, L-cysteine hydrochloride monohydrate.
In another embodiment of the invention, antioxidant can be selected from sodium pyrosulfite, sodium hydrogensulfite, vitamin C, paddy
One of sweet peptide of Guang is several.Vitamin C participates in a variety of oxidation-reduction reactions of human body, and has detoxication.Dimension life
Plain C participates in the metabolism and oxidation process of sugar in human body, and prevents the generation of carcinogen (nitrosamine).Vitamin C can be gone
Except intracellular harmful free radical.Preferably, when discovery sodium pyrosulfite is with vitamin C, it can achieve better antioxygen
Change effect.In addition, it is found that cosolvent L-cysteine hydrochloride is cooperateed with can also play when sodium sulfite and vitamin C
Antioxidation.
In another embodiment of the present invention, the Edaravone Injection includes: the Edaravone of 30 parts by weight.According to reaching
The sodium chloride that injection further includes 800-1000 parts by weight, such as the chlorination of 800,850,900,950,1000 parts by weight are given in drawing
Sodium.Edaravone Injection can also include the sodium pyrosulfite of 15-25 parts by weight, such as 15,18,20,23,25 parts by weight
Sodium pyrosulfite.Edaravone Injection can also include the vitamin C of 5-15 parts by weight, such as 5,8,10,12,15 parts by weight
Vitamin C.Edaravone Injection can also include 5-15 parts by weight L-cysteine hydrochloride, such as 5,8,10,12,
The L-cysteine hydrochloride of 15 parts by weight.
Preferably, in one embodiment of the invention, the Edaravone Injection include: 30mg Edaravone,
900mg sodium chloride, 10mg vitamin C, 10mg L-cysteine hydrochloride, infuses the Edaravone at 20mg sodium pyrosulfite
Penetrate the water for injection that liquid product is 100ml.Experiment shows that above-mentioned formula range and formula can reach good anti-oxidant effect
Fruit.
Above-mentioned Edaravone Injection maximises antioxidant effect from square degree.In order to enable Edaravone infusion group
The antioxidant effect of part still is able to play a role over time, in another embodiment provided by the invention, uses
Soft bag technique with oxygen absorption function.
In one embodiment of this invention, the soft bag includes film, and the film includes outer layer, middle layer and internal layer；Outer layer
Such as can be polyamide and be made, internal layer for example can be polyethylene and be made.The middle layer includes polypropylene, has unsaturation
The polyenoid quasi polymer and transition metal salt of double bond.
Middle layer has oxygen absorption function due to its constituent, can be in the prolonged preservation of Edaravone Injection
Constant absorption oxygen in the process reaches long-acting dynamic antiradiation drug oxidative function.The oxygen uptake principle of middle layer is mainly by with mistake
While crossing the oxidation scission reaction production alcohol, aldehyde, ketone, carboxylic acid for the polyenoid quasi polymer that metal salt is catalyst, oxygen is absorbed.It is poly-
Propylene plays the role of film layer support in the intermediate layer.
In another embodiment of the present invention, middle layer includes the polypropylene for occupying entire intermediate layer weight 85-99%, example
Such as 85%, 90%, 92%, 97%, 99%；Middle layer include occupy entire intermediate layer weight 1-15% there is unsaturated double-bond
Polyenoid quasi polymer, such as 1%, 3%, 5%, 8%, 10%, 12%, 15% etc.；Middle layer further includes occupying entire centre
The transition metal salt of layer weight 1-15ppm, such as 1ppm, 3ppm, 5ppm, 8ppm, 10ppm, 12ppm, 15ppm etc..
In another embodiment of the invention, it is preferred that polyenoid quasi polymer with unsaturated double-bond is poly- isoamyl two
Alkene；The transition metal salt is cobaltous octadecanate.
The embodiment of the invention also provides a kind of preparation methods of above-mentioned Edaravone infusion set, comprising:
Step 1: osmotic pressure regulator being dissolved in water for injection and forms the first solution.
In this step, for example, by the sodium chloride of recipe quantity be dissolved in 40-60 DEG C nitrogen charging degassing water for injection in.
Step 2: antioxidant, cosolvent being dissolved in water for injection and form the second solution, and second solution is poured into
In first solution, third solution is formed.
In this step, such as the sodium pyrosulfite, vitamin C, L-cysteine hydrochloride of recipe quantity are dissolved in and rush nitrogen
In the water for injection of degassing, formed the second solution, and by the second solution pour into the first solution in step 1 formed third it is molten
Liquid.
Step 3: Edaravone is added in the third solution, is dissolved by heating at 50 DEG C or less, adjusted after cooling pH to
3.0-4.5。
The Edaravone of recipe quantity is dissolved in third solution.In order to promote the dissolution of Edaravone, can be lower than
Stirring and dissolving at a temperature of 50 DEG C.After the cooling period for example with salt acid for adjusting pH to 3.0-4.5.The concentration of hydrochloric acid used is, for example,
0.1mol/L.PH value after the adjusting is, for example, 3.0,3.2,3.5,3.8,4.0,4.2,4.5.
Step 4: water for injection being added in the third solution and supplies recipe quantity.
In this step, in the third solution for having completed pH adjusting, the water for injection of the nitrogen charging degassing of recipe quantity is supplied,
Such as complement to 100L.
Step 5: the third solution being subjected to micro-pore-film filtration and is poured into the soft bag, is sterilized.
In this step, the third solution for supplying water for injection is filtered using microporous barrier.Such as select 0.22 μm of hole
The microporous barrier of diameter is filtered.It is further alternative, intermediates content and pH value are measured after filtering, are poured into phase after qualification
It answers in the soft bag of capacity, such as in the soft bag of 100mL specification.High-temperature sterilization finally is carried out to packaged soft bag.Finally carry out
Lamp inspection is packed up to final products.
In order to which preferably the present invention will be described, several specific embodiments are set forth below and are illustrated.
According to following table prescription, embodiment and comparative example are set.
* note: sodium hydrogensulfite is replaced with
The embodiment and comparative example prepared according to each component content in upper table is as follows.
Embodiment 1
Weigh 900g sodium chloride be dissolved in 75L, 50 DEG C nitrogen charging degassing water for injection in, formed the first solution.Weigh 18g
Sodium pyrosulfite, 12g vitamin C, 10g L-cysteine hydrochloride monohydrate add the degassing water for injection dissolution of 10L nitrogen charging,
Form the second solution.Second solution is mixed with the first solution, 30g Edaravone is added.45 DEG C are heated to, keeps Edaravone molten
Solution forms third solution.0.1mol/L salt acid for adjusting pH will be used to 4.0 after the cooling of third solution.The after completing pH and adjusting
In three solution, the water for injection of nitrogen charging degassing is supplied to 100L.It is 0.22 μm of filtering with microporous membrane with pore size, in measurement
Mesosome content and pH value distinguish encapsulating in 1000 100ml soft bags after qualified.Autoclaving steam sterilization under pressure 30 minutes at 115 DEG C.
Carry out lamp inspection, packaging finally to get final infusion set.Wherein, soft bag outer layer is film layer made of polyamide, and internal layer is poly- second
Film layer made of alkene, middle layer are film made of the polypropylene, the polyisoprene of 10wt% and the cobaltous octadecanate of 10ppm of 90wt%
Layer.
Embodiment 2
Weigh 900g sodium chloride be dissolved in 75L, 50 DEG C nitrogen charging degassing water for injection in, formed the first solution.Weigh 20g
Sodium pyrosulfite, 12g vitamin C, 8g L-cysteine hydrochloride monohydrate add the degassing water for injection dissolution of 10L nitrogen charging,
Form the second solution.Second solution is mixed with the first solution, 30g Edaravone is added.45 DEG C are heated to, keeps Edaravone molten
Solution forms third solution.0.1mol/L salt acid for adjusting pH will be used to 4.0 after the cooling of third solution.The after completing pH and adjusting
In three solution, the water for injection of nitrogen charging degassing is supplied to 100L.It is 0.22 μm of filtering with microporous membrane with pore size, in measurement
Mesosome content and pH value distinguish encapsulating in 1000 100ml soft bags after qualified.Autoclaving steam sterilization under pressure 30 minutes at 115 DEG C.
Carry out lamp inspection, packaging finally to get final infusion set.Wherein, soft bag outer layer is film layer made of polyamide, and internal layer is poly- second
Film layer made of alkene, middle layer are film made of the polypropylene, the polyisoprene of 10wt% and the cobaltous octadecanate of 10ppm of 90wt%
Layer.
Embodiment 3
Weigh 900g sodium chloride be dissolved in 75L, 50 DEG C nitrogen charging degassing water for injection in, formed the first solution.Weigh 15g
Sodium pyrosulfite, 13g vitamin C, 12g L-cysteine hydrochloride monohydrate add the degassing water for injection dissolution of 10L nitrogen charging,
Form the second solution.Second solution is mixed with the first solution, 30g Edaravone is added.45 DEG C are heated to, keeps Edaravone molten
Solution forms third solution.0.1mol/L salt acid for adjusting pH will be used to 4.0 after the cooling of third solution.The after completing pH and adjusting
In three solution, the water for injection of nitrogen charging degassing is supplied to 100L.It is 0.22 μm of filtering with microporous membrane with pore size, in measurement
Mesosome content and pH value distinguish encapsulating in 1000 100ml soft bags after qualified.Autoclaving steam sterilization under pressure 30 minutes at 115 DEG C.
Carry out lamp inspection, packaging finally to get final infusion set.Wherein, soft bag outer layer is film layer made of polyamide, and internal layer is poly- second
Film layer made of alkene, middle layer are film made of the polypropylene, the polyisoprene of 10wt% and the cobaltous octadecanate of 10ppm of 90wt%
Layer.
Embodiment 4
Weigh 900g sodium chloride be dissolved in 75L, 50 DEG C nitrogen charging degassing water for injection in, formed the first solution.Weigh 20g
Sodium pyrosulfite, 8g vitamin C, 12g L-cysteine hydrochloride monohydrate add the degassing water for injection dissolution of 10L nitrogen charging,
Form the second solution.Second solution is mixed with the first solution, 30g Edaravone is added.45 DEG C are heated to, keeps Edaravone molten
Solution forms third solution.0.1mol/L salt acid for adjusting pH will be used to 4.0 after the cooling of third solution.The after completing pH and adjusting
In three solution, the water for injection of nitrogen charging degassing is supplied to 100L.It is 0.22 μm of filtering with microporous membrane with pore size, in measurement
Mesosome content and pH value distinguish encapsulating in 1000 100ml soft bags after qualified.Autoclaving steam sterilization under pressure 30 minutes at 115 DEG C.
Carry out lamp inspection, packaging finally to get final infusion set.Wherein, soft bag outer layer is film layer made of polyamide, and internal layer is poly- second
Film layer made of alkene, middle layer are film made of the polypropylene, the polyisoprene of 10wt% and the cobaltous octadecanate of 10ppm of 90wt%
Layer.
Embodiment 5
Weigh 900g sodium chloride be dissolved in 75L, 50 DEG C nitrogen charging degassing water for injection in, formed the first solution.Weigh 20g
Sodium pyrosulfite, 10g vitamin C, 10g L-cysteine hydrochloride monohydrate add the degassing water for injection dissolution of 10L nitrogen charging,
Form the second solution.Second solution is mixed with the first solution, 30g Edaravone is added.45 DEG C are heated to, keeps Edaravone molten
Solution forms third solution.0.1mol/L salt acid for adjusting pH will be used to 4.0 after the cooling of third solution.The after completing pH and adjusting
In three solution, the water for injection of nitrogen charging degassing is supplied to 100L.It is 0.22 μm of filtering with microporous membrane with pore size, in measurement
Mesosome content and pH value distinguish encapsulating in 1000 100ml soft bags after qualified.Autoclaving steam sterilization under pressure 30 minutes at 115 DEG C.
Carry out lamp inspection, packaging finally to get final infusion set.Wherein, soft bag outer layer is film layer made of polyamide, and internal layer is poly- second
Film layer made of alkene, middle layer are film made of the polypropylene, the polyisoprene of 10wt% and the cobaltous octadecanate of 10ppm of 90wt%
Layer.
Comparative example 1
Weigh 900g sodium chloride be dissolved in 75L, 50 DEG C nitrogen charging degassing water for injection in, formed the first solution.Weigh 20g
Sodium pyrosulfite, 10g sodium hydrogensulfite, 10g L-cysteine hydrochloride monohydrate add 10L nitrogen charging degassing injection water-soluble
Solution forms the second solution.Second solution is mixed with the first solution, 30g Edaravone is added.45 DEG C are heated to, Yi Dala is made
Dissolution is given, third solution is formed.0.1mol/L salt acid for adjusting pH will be used to 4.0 after the cooling of third solution.After completing pH and adjusting
Third solution in, supply the water for injection of nitrogen charging degassing to 100L.The filtering with microporous membrane for being 0.22 μm with pore size is surveyed
Determine intermediates content and pH value, encapsulating is distinguished after qualified in 1000 100ml soft bags.The autoclaving steam sterilization under pressure 30 at 115 DEG C
Minute.Carry out lamp inspection, packaging finally to get final infusion set.Wherein the soft bag is common PVC soft bag.
Comparative example 2
Weigh 900g sodium chloride be dissolved in 75L, 50 DEG C nitrogen charging degassing water for injection in, formed the first solution.Weigh 20g
Sodium pyrosulfite, 20g vitamin C add the degassing water for injection dissolution of 10L nitrogen charging, form the second solution.By the second solution and first
Solution mixing, is added 30g Edaravone.45 DEG C are heated to, Edaravone is dissolved, forms third solution.Third solution is cold
But afterwards with 0.1mol/L salt acid for adjusting pH to 4.0.In the third solution after completing pH and adjusting, the injection of nitrogen charging degassing is supplied
Water is to 100L.The filtering with microporous membrane for being 0.22 μm with pore size measures intermediates content and pH value, distinguishes encapsulating after qualified
In 1000 100ml soft bags.Autoclaving steam sterilization under pressure 30 minutes at 115 DEG C.Carry out lamp inspection, packaging finally to get final defeated
Liquid component.Wherein the soft bag is common PVC soft bag.
Comparative example 3
Weigh 900g sodium chloride be dissolved in 75L, 50 DEG C nitrogen charging degassing water for injection in, formed the first solution.Weigh 20g
Sodium pyrosulfite, 10g vitamin C, 10g L-cysteine hydrochloride monohydrate add the degassing water for injection dissolution of 10L nitrogen charging,
Form the second solution.Second solution is mixed with the first solution, 30g Edaravone is added.45 DEG C are heated to, keeps Edaravone molten
Solution forms third solution.0.1mol/L salt acid for adjusting pH will be used to 4.0 after the cooling of third solution.The after completing pH and adjusting
In three solution, the water for injection of nitrogen charging degassing is supplied to 100L.It is 0.22 μm of filtering with microporous membrane with pore size, in measurement
Mesosome content and pH value distinguish encapsulating in 1000 100ml soft bags after qualified.Autoclaving steam sterilization under pressure 30 minutes at 115 DEG C.
Carry out lamp inspection, packaging finally to get final infusion set.Wherein the soft bag is common PVC soft bag.
Performance test
1, the infusion set room temperature in embodiment and comparative example was carried out to the detection of explanation product, inspection by the 10th day
Survey result such as following table.
| Prescription | Compare ingredient | Catabolite (%) |
| Embodiment 1 | Sodium pyrosulfite, vitamin C, L-cysteine hydrochloride | 0.09 |
| Embodiment 2 | Sodium pyrosulfite, vitamin C, L-cysteine hydrochloride | 0.12 |
| Embodiment 3 | Sodium pyrosulfite, vitamin C, L-cysteine hydrochloride | 0.14 |
| Embodiment 4 | Sodium pyrosulfite, vitamin C, L-cysteine hydrochloride | 0.17 |
| Embodiment 5 | Sodium pyrosulfite, vitamin C, L-cysteine hydrochloride | 0.07 |
| Comparative example 1 | Sodium pyrosulfite, sodium hydrogensulfite, L-cysteine hydrochloride | 0.35 |
| Comparative example 2 | Sodium pyrosulfite, vitamin C | 0.19 |
| Comparative example 3 | Sodium pyrosulfite, vitamin C, L-cysteine hydrochloride | 0.07 |
Pass through above-mentioned testing result, it can be seen that the Edaravone using sodium pyrosulfite, vitamin C as antioxidant
Injection has preferable stability.And further using L-cysteine hydrochloride as cosolvent and antioxidant according to reaching
Drawing gives injection with better stability.
2, accelerated test
The infusion set in above-described embodiment and comparative example is taken, is placed 6 months at 40 DEG C, and in 1,2,3, the end of month in June
It is detected, as a result see the table below.
It can see by above-mentioned testing result, using the Edaravone Injection of the soft bag with oxygen absorption function in length
Time has better stability in saving.
The above description is merely a specific embodiment, but scope of protection of the present invention is not limited thereto, any
Those familiar with the art in the technical scope disclosed by the present invention, can easily think of the change or the replacement, and should all contain
Lid is within protection scope of the present invention.Therefore, protection scope of the present invention should be based on the protection scope of the described claims.
Claims (10)
1. a kind of Edaravone infusion set, which is characterized in that described according to reaching including Edaravone Injection and for accommodating
Draw the soft bag for giving injection；
The Edaravone Injection includes: Edaravone, osmotic pressure regulator, antioxidant, cosolvent and water for injection；
The Edaravone Injection volume is about or equal to 100mL.
2. Edaravone infusion set according to claim 1, which is characterized in that the osmotic pressure regulator is chlorination
Sodium.
3. Edaravone infusion set according to claim 1, which is characterized in that the antioxidant includes sodium pyrosulfite
And vitamin C.
4. Edaravone infusion set according to claim 1, which is characterized in that the cosolvent includes L-cysteine
Hydrochloride.
5. Edaravone infusion set according to claim 1, which is characterized in that the Edaravone Injection includes:
The Edaravone of 30 parts by weight, the sodium chloride of 800-1000 parts by weight, the sodium pyrosulfite of 15-25 parts by weight, 5-15 weight
Measure the vitamin C of part and the L-cysteine hydrochloride of 5-15 parts by weight.
6. Edaravone infusion set according to claim 5, which is characterized in that the Edaravone Injection includes:
30mg Edaravone, 900mg sodium chloride, 20mg sodium pyrosulfite, 10mg vitamin C, 10mg L-cysteine hydrochloric acid
Salt, the water for injection for making the Edaravone Injection volume 100ml.
7. Edaravone infusion set according to claim 1, which is characterized in that the soft bag includes film, the film packet
Include outer layer, middle layer and internal layer；
The middle layer includes polypropylene, polyenoid quasi polymer with unsaturated double-bond and transition metal salt.
8. Edaravone infusion set according to claim 7, which is characterized in that
The middle layer include the polypropylene for occupying entire intermediate layer weight 85-99%, 1-15% it is with unsaturated double-bond
The transition metal salt of polyenoid quasi polymer, 1-15ppm.
9. Edaravone infusion set according to claim 8, which is characterized in that polyenoid with unsaturated double-bond is birdsed of the same feather flock together
Conjunction object is polyisoprene；The transition metal salt is cobaltous octadecanate.
10. the preparation method of the described in any item Edaravone infusion sets of claim 1-9 characterized by comprising
Osmotic pressure regulator is dissolved in water for injection and forms the first solution；
Antioxidant, cosolvent are dissolved in water for injection and form the second solution, and it is molten that second solution poured into described first
In liquid, third solution is formed；
Edaravone is added in the third solution, is dissolved by heating at 50 DEG C or less, adjusts pH to 3.0-4.5 after cooling；
Water for injection is added in the third solution and supplies recipe quantity；
The third solution is subjected to micro-pore-film filtration and is poured into the soft bag, is sterilized.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910072044.8A CN109674746A (en) | 2019-01-25 | 2019-01-25 | A kind of Edaravone infusion set |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910072044.8A CN109674746A (en) | 2019-01-25 | 2019-01-25 | A kind of Edaravone infusion set |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109674746A true CN109674746A (en) | 2019-04-26 |
Family
ID=66194781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910072044.8A Pending CN109674746A (en) | 2019-01-25 | 2019-01-25 | A kind of Edaravone infusion set |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109674746A (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1181089A (en) * | 1995-01-24 | 1998-05-06 | 纳幕尔杜邦公司 | 'Alpha'-olefines and olefin polymers and processes therefor |
| CN1449754A (en) * | 2003-04-16 | 2003-10-22 | 浙江震元制药有限公司 | Edaravone medicine composition and preparation thereof |
| CN1636630A (en) * | 2003-12-03 | 2005-07-13 | 可乐丽股份有限公司 | Oxygen absorption resin composition |
| CN1849371A (en) * | 2003-07-10 | 2006-10-18 | 东洋制罐株式会社 | Oxygen-absorbing resin composition |
| JP2010081971A (en) * | 2008-09-29 | 2010-04-15 | Terumo Corp | Premix drug product of edaravone |
| WO2010131038A2 (en) * | 2009-05-13 | 2010-11-18 | Isis Innovation Limited | Steroid containing composition and uses thereof |
| CN102335129A (en) * | 2011-08-03 | 2012-02-01 | 天津市嵩锐医药科技有限公司 | Edaravone medicinal composition for injection and preparation method thereof |
| CN103349776A (en) * | 2013-07-17 | 2013-10-16 | 北京普瑞博思投资有限公司 | Edaravone injection solution and preparation method thereof |
| CN104069101A (en) * | 2014-06-09 | 2014-10-01 | 广东利泰制药股份有限公司 | Amino acid injection for non-PVC (polyvinyl chloride) three-layer co-extruded transfusion bag and preparation process of amino acid injection |
| CN105616346A (en) * | 2016-03-09 | 2016-06-01 | 海南合瑞制药股份有限公司 | Edaravone medicine composition and preparation method thereof |
| CN108324683A (en) * | 2017-01-18 | 2018-07-27 | 江苏正大丰海制药有限公司 | A kind of big infusion Edaravone Injection and its preparation process of stabilization |
-
2019
- 2019-01-25 CN CN201910072044.8A patent/CN109674746A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1181089A (en) * | 1995-01-24 | 1998-05-06 | 纳幕尔杜邦公司 | 'Alpha'-olefines and olefin polymers and processes therefor |
| CN1449754A (en) * | 2003-04-16 | 2003-10-22 | 浙江震元制药有限公司 | Edaravone medicine composition and preparation thereof |
| CN1849371A (en) * | 2003-07-10 | 2006-10-18 | 东洋制罐株式会社 | Oxygen-absorbing resin composition |
| CN1636630A (en) * | 2003-12-03 | 2005-07-13 | 可乐丽股份有限公司 | Oxygen absorption resin composition |
| JP2010081971A (en) * | 2008-09-29 | 2010-04-15 | Terumo Corp | Premix drug product of edaravone |
| WO2010131038A2 (en) * | 2009-05-13 | 2010-11-18 | Isis Innovation Limited | Steroid containing composition and uses thereof |
| CN102335129A (en) * | 2011-08-03 | 2012-02-01 | 天津市嵩锐医药科技有限公司 | Edaravone medicinal composition for injection and preparation method thereof |
| CN103349776A (en) * | 2013-07-17 | 2013-10-16 | 北京普瑞博思投资有限公司 | Edaravone injection solution and preparation method thereof |
| CN104069101A (en) * | 2014-06-09 | 2014-10-01 | 广东利泰制药股份有限公司 | Amino acid injection for non-PVC (polyvinyl chloride) three-layer co-extruded transfusion bag and preparation process of amino acid injection |
| CN105616346A (en) * | 2016-03-09 | 2016-06-01 | 海南合瑞制药股份有限公司 | Edaravone medicine composition and preparation method thereof |
| CN108324683A (en) * | 2017-01-18 | 2018-07-27 | 江苏正大丰海制药有限公司 | A kind of big infusion Edaravone Injection and its preparation process of stabilization |
Non-Patent Citations (2)
| Title |
|---|
| 冯雪松等: "维生素C注射液抗氧剂的选择", 《实用药物与临床》 * |
| 邢诒刚: "《鼻咽癌放疗后神经损伤学 普及版》", 31 July 2018 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104586885A (en) | Compound sodium bicarbonate electrolyte injection composition and preparation method thereof | |
| CN106061467A (en) | Process for producing a stable low concentration, injectable solution of noradrenaline | |
| TWI597070B (en) | Infusion preparation | |
| CN109432123A (en) | A kind of compound electrolyte glucose injection and preparation method thereof | |
| KR20240013160A (en) | Ready-to-use parenteral nutritional products | |
| CN102091028A (en) | Edaravone injection and preparation method thereof | |
| US8829054B1 (en) | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container | |
| JP5537104B2 (en) | Antiemetic | |
| CN105726473A (en) | Oral solution of tomoxetine or medicinal salt thereof and preparation method thereof | |
| JPH06312923A (en) | Nutrient infusion solution for peripheral venous nutrition | |
| CN109674746A (en) | A kind of Edaravone infusion set | |
| CN102718693B (en) | Carbazochrome sodium sulfonate compound and composition thereof | |
| CN112245387B (en) | Composition and preparation method of m-hydroxylamine bitartrate injection | |
| JP7519108B2 (en) | Pharmaceutical composition and method for producing same | |
| CN110302389B (en) | Anti-angiogenesis hydrogel sustained-release preparation and application thereof | |
| US11147834B2 (en) | Composition for treatment or prevention of age-related macular degeneration comprising molecular hydrogen | |
| CN106902144B (en) | Preparation method of composition for injection of medium-long-chain fat emulsion, amino acid and glucose and composition | |
| AU2018332212B2 (en) | Topical formulations of chloroprocaine | |
| CN115811988A (en) | Blood purification molecule concentrate and preparation method and application thereof | |
| CN107789365A (en) | The medical composition and its use of various trace elements V | |
| CN110200905A (en) | A kind of ambroxol hydrochloride composition and its injection and application | |
| CN102784098A (en) | Magnesium valproate injection and preparation method thereof | |
| CN108451974A (en) | A kind of aspartic acid Multiple electrolytes injection and preparation method thereof | |
| CN106361691A (en) | Medical plastic packaging liquid preparation, and sterilization method and preparation method thereof | |
| CN102600143B (en) | Vinpocetine medicament composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Room 210, floor 2, building 8, Shoubao Zhuang Hongkun financial Valley, Xihongmen Town, Daxing District, Beijing 100162 Applicant after: Beijing Taiyangsheng high tech Pharmaceutical Research Co.,Ltd. Address before: Room 210, floor 2, building 8, Shoubao Zhuang Hongkun financial Valley, Xihongmen Town, Daxing District, Beijing 100162 Applicant before: TAI YANG SHENG HIGH-TECH PHARMACEUTICAL RESEARCH Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20211028 Address after: 236800 5th floor, caohong Road comprehensive office building, high tech Zone, Bozhou City, Anhui Province Applicant after: Taiyangsheng (Bozhou) Biomedical Technology Co.,Ltd. Address before: Room 210, floor 2, building 8, Shoubao Zhuang Hongkun financial Valley, Xihongmen Town, Daxing District, Beijing 100162 Applicant before: Beijing Taiyangsheng high tech Pharmaceutical Research Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190426 |
|
| WD01 | Invention patent application deemed withdrawn after publication |